For PTX-targeted delivery, YSAYPDSVPMMS (YSA) peptide was successfully tested to selectively target Ephrin type-A receptor 2 (EphA2) activation when anchored with liposomal docetaxel (a common clinical formulation of PTX) in A549 lung cancer cell line [61]. Here, EPHA2 is linked to lung carcinoma.